Menu Search
Equities

Kaken Pharmaceutical Co Ltd

KKPCF:PKL

Kaken Pharmaceutical Co Ltd

Actions
  • Price (USD)24.01
  • Today's Change0.00 / 0.00%
  • Shares traded200.00
  • 1 Year change--
  • Beta--
Data delayed at least 15 minutes, as of Nov 05 2024 20:05 GMT.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

KAKEN PHARMACEUTICAL CO., LTD. is a Japan-based company engaged in the production and sale of pharmaceutical products. The Company operates in two business segments. The Pharmaceutical segment involves in the manufacture and sale of pharmaceuticals, medical devices and agricultural drugs. The Real Estate segment is engaged in the leasing of real estate.

  • Revenue in JPY (TTM)87.25bn
  • Net income in JPY18.24bn
  • Incorporated1948
  • Employees1.14k
  • Location
    Kaken Pharmaceutical Co Ltd20F, Bunkyo Green Court Center Office2-28-8, HonkomagomeBUNKYO-KU 113-8650JapanJPN
  • Phone+81 359775001
  • Fax+81 359775131
  • Websitehttps://www.kaken.co.jp/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status		4521:TYO since
announced		Transaction
value
Eisai Co Ltd-Merislon & MyonalAnnounced29 Mar 202429 Mar 2024Announced29.92%25.10m
Data delayed at least 20 minutes, as of Nov 21 2024 06:30 GMT.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.